Qiming Venture Partners Closes $1.1 Billion Fund

Shanghai – April 20, 2020 – Cooley advised Qiming Venture Partners on the closing of its seventh fund at the target amount of $1.1 billion. Fund VII, which closed despite the COVID-19 pandemic and geopolitical uncertainties, will focus on early-stage healthcare and technology, media and telecommunications investments. Partner Jordan Silber led the Cooley team advising Qiming. 

As in prior funds, the majority of the capital raised for Fund VII comes from a prestigious group of endowments, foundations, family offices and private pensions. Qiming anticipates investing the new fund in areas such as biopharma, medtech, diagnostics, healthcare services, information technology, artificial intelligence, enterprise services, consumer internet and ecommerce.  

Since its debut in 2006, Qiming has backed 350+ fast-growing and innovative companies, 110+ which are publicly traded or have achieved exit through M&A and other means, and 30+ companies that have reached unicorn status. Many of Qiming’s portfolio companies are today’s most influential brands in their respective sectors, including Xiaomi, Meituan Dianping, UBTech, Bilibili, Roborock, Tigermed, Zai Lab, Venus MedTec, CanSino, Schrödinger, Sanyou Medical, AmoyDx, Berry Genomics and WeDoctor – and a large portion are also involved in pandemic-related efforts.

“As the world combats the COVID-19 pandemic, we are proud that many of our portfolio companies play a critical role in providing products and services both to the frontline medical care as well as to the backend supports,” a Qiming spokesperson said in a news release. “Qiming is committed to continue investing in great entrepreneurs for the betterment of humanity. We take great pride in bringing long-term value to all societies.”

Cooley has been advising Qiming for nearly a decade, assisting in fund formation and financing transactions. The firm is fund formation counsel to 550+ fund organizations worldwide, including 50+ fund managers with their primary operations in China.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.